echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Brief analysis on the investment risk of assisted reproduction Market

    Brief analysis on the investment risk of assisted reproduction Market

    • Last Update: 2020-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Human assisted reproductive technology refers to the technology of using medical aids to make infertile couples pregnant, including artificial insemination, in vitro fertilization embryo transfer and its derivative technology In vitro fertilization and embryo transfer are used for in vitro fertilization At present, IVF-ET, ISCI and PGD / PGs are three generations of IVF-ET In 1978, the world's first test tube baby was born, assisted reproductive technology has entered a rapid development stage In 1984, the Third Hospital of Peking University, Peking Union Medical College Hospital and Hunan Medical University cooperated to produce the first test tube baby in mainland China Clinical common reproductive disorders include polycystic ovarian syndrome, ovarian dysfunction, endometriosis, recurrent abortion, male azoospermia and oligospermia Secondly, with the opening of the second birth policy, the proportion of the elderly women over 35 years old increased, the quality of eggs decreased and the pregnancy rate decreased The incidence rate of infertility in China has been increasing No.3 Hospital of Peking University has conducted 3 epidemiological surveys of large infertility in China The 10, 8 and 9 provinces and cities have conducted 16886 stages, 18571 and 13071 people in different stages The infertility rates were 11.9% in 2007, 15.5% in 2010 and 18.7% in 2013 The market of assisted reproduction mainly consists of three fields: medical devices, testing reagents and biomedicine in the upstream, assisted reproduction services in the middle and assisted reproductive medical institutions in the downstream Among them, the upper reaches of the field of adjuvant drugs and the lower reaches of the assisted reproductive medical institutions have the highest profits The basis of assisted reproduction is ovulation, and the drugs involved are all around ovulation With Merck and Abbott as the representatives, foreign enterprises occupy a monopoly position in the field of assisted reproductive drugs Merck's recombinant human follicle stimulating hormone products use gene recombination technology, which is relatively leading Chinese enterprises include Lizhu group, Zhengda Tianqing, Changchun Jinsai, Xianju pharmaceutical, etc The urofollicle stimulating hormone of Lizhu group belongs to the original urine product, occupying the middle market In 2018, Zhengda Tianqing's acetic acid ganirick injection was successfully launched, which also broke Merck's monopoly The products of assisted reproductive medical devices are mainly egg taking needle, microinjection needle and embryo transfer catheter equipment, which are basically monopolized by foreign enterprises, such a s vitrolife in Sweden, William a.cook in Australia, cook in the United States, Wallace in the United Kingdom, sun medical in Japan, genetics in Belgium, origio a / s in Denmark, etc.; Chinese enterprises include Shandong Weigao, Rhein precision medical, etc Downstream auxiliary reproductive institutions include Peking University Third Hospital, Peking Union Medical College Hospital, CITIC Xiangya reproductive and genetic hospital, Jinxin reproductive medical group, Aviv medical group, etc In July 2016, the national development and Reform Commission issued the opinions on promoting the price reform of medical services, which allowed the independent pricing of special needs medical services and the special needs medical services of assisted reproductive services, and the price began to rise On June 25, 2019, Jinxin reproductive was listed in Hong Kong stock market According to its annual report, the average annual growth rate of its main business income from 2016 to June 2019 exceeded 60% (Figure 1) Figure 1: Jinxin's operating revenue in June 2016-2019 (unit: 100 million yuan) Source: public information, sgrcr collation Downstream investment risk tips Although there are a number of top talents in China, such as Lu Guangxiu and Zhang Lizhu, at present, there are few domestic colleges and universities to set up the assisted reproduction discipline, and most of the employees are transferred from other majors, and there is no systematic and specialized learning, resulting in the lack of conventional talents; the time for the regular hospitals to carry out the assisted reproduction project is still short, and the experience is insufficient, which has not reached the stage of large-scale and high-quality replication At present, the system of assisted reproductive technology in China is not perfect, which leads to the wide variety of screening and the high cost of PGs / PGD technology Therefore, China's IVF technology mostly uses the first and second generation technology, and only a few institutions carry out the third generation technology, such as CITIC Xiangya and Beijing Medical College.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.